• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估野生型转甲状腺素蛋白淀粉样心肌病患者的转甲状腺素蛋白不稳定性。

Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy.

机构信息

Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Central Research Laboratories, Sysmex Corporation, Kobe, Japan.

出版信息

Sci Rep. 2024 Sep 3;14(1):20508. doi: 10.1038/s41598-024-71446-8.

DOI:10.1038/s41598-024-71446-8
PMID:39227655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11371834/
Abstract

The pathophysiology of variant transthyretin (TTR) amyloidosis (ATTRv) is associated with destabilizing mutations in the TTR tetramer. However, why TTR with a wild-type genetic sequence misfolds and aggregates in wild-type transthyretin amyloidosis (ATTRwt) is unknown. Here, we evaluate kinetic TTR stability with a newly developed ELISA system in combination with urea-induced protein denaturation. Compared with that in control patients, endogenous TTR in patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) exhibited thermodynamic instability, indicating that circulating TTR instability may be associated with the pathogenesis of ATTRwt as well as ATTRv. Our findings provide new insight into the underlying mechanisms of ATTRwt.

摘要

变异转甲状腺素蛋白(TTR)淀粉样变(ATTRv)的病理生理学与 TTR 四聚体的不稳定突变有关。然而,为什么野生型 TTR 会发生错误折叠和聚集在野生型转甲状腺素蛋白淀粉样变(ATTRwt)中尚不清楚。在这里,我们使用新开发的 ELISA 系统结合尿素诱导的蛋白质变性来评估 TTR 的动力学稳定性。与对照患者相比,野生型转甲状腺素蛋白淀粉样心肌病(ATTRwt-CM)患者的内源性 TTR 表现出热力学不稳定性,这表明循环 TTR 的不稳定性可能与 ATTRwt 以及 ATTRv 的发病机制有关。我们的发现为 ATTRwt 的潜在机制提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/b7362a74a44b/41598_2024_71446_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/677b11c996d6/41598_2024_71446_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/e0d674440f66/41598_2024_71446_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/aab1d509b549/41598_2024_71446_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/4337c1768b0c/41598_2024_71446_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/b7362a74a44b/41598_2024_71446_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/677b11c996d6/41598_2024_71446_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/e0d674440f66/41598_2024_71446_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/aab1d509b549/41598_2024_71446_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/4337c1768b0c/41598_2024_71446_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38ee/11371834/b7362a74a44b/41598_2024_71446_Fig5_HTML.jpg

相似文献

1
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy.评估野生型转甲状腺素蛋白淀粉样心肌病患者的转甲状腺素蛋白不稳定性。
Sci Rep. 2024 Sep 3;14(1):20508. doi: 10.1038/s41598-024-71446-8.
2
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.通过人血浆中亚基交换对转甲状腺素蛋白动力学稳定剂进行盲法效力度比较。
Amyloid. 2021 Mar;28(1):24-29. doi: 10.1080/13506129.2020.1808783. Epub 2020 Aug 18.
3
Cardiac sympathetic denervation in wild-type transthyretin amyloidosis.野生型转甲状腺素淀粉样变心肌病心脏去交感神经支配。
Amyloid. 2020 Dec;27(4):237-243. doi: 10.1080/13506129.2020.1769059. Epub 2020 May 22.
4
Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.遗传性与野生型转甲状腺素蛋白淀粉样心肌病老年患者的患病率、特征及预后
Eur J Heart Fail. 2023 Apr;25(4):515-524. doi: 10.1002/ejhf.2776. Epub 2023 Jan 30.
5
Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?V142I 相关变异转甲状腺素蛋白淀粉样心肌病的深度表型分析:与野生型转甲状腺素蛋白淀粉样变性不同?
Eur J Heart Fail. 2024 Feb;26(2):383-393. doi: 10.1002/ejhf.3088. Epub 2024 Jan 28.
6
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.塔非酰胺在转甲状腺素蛋白淀粉样心肌病中的作用:对转甲状腺素蛋白稳定性及临床结局的影响
Circ Heart Fail. 2015 May;8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890. Epub 2015 Apr 14.
7
First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.首例挪威遗传性ATTR 淀粉样变伴新型转甲状腺素蛋白变异。
Scand Cardiovasc J. 2023 Dec;57(1):2174269. doi: 10.1080/14017431.2023.2174269.
8
Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.转甲状腺素相关与轻链心脏淀粉样变性的左心室结构和功能。
Circulation. 2014 May 6;129(18):1840-9. doi: 10.1161/CIRCULATIONAHA.113.006242. Epub 2014 Feb 21.
9
Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).野生型转甲状腺素蛋白淀粉样变性(ATTRwt)中转甲状腺素蛋白基因的遗传变异。
Hum Genet. 2015 Jan;134(1):111-21. doi: 10.1007/s00439-014-1499-0. Epub 2014 Nov 4.
10
Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.与疾病相关的突变会影响 BC 环的柔韧性,从而引发甲状腺素运载蛋白四聚体的远程不稳定性和聚集。
J Biol Chem. 2021 Sep;297(3):101039. doi: 10.1016/j.jbc.2021.101039. Epub 2021 Jul 31.

引用本文的文献

1
Silencers versus stabilizers in amyloid cardiomyopathy. Are we asking the wrong questions?淀粉样心肌病中的沉默因子与稳定剂。我们问错问题了吗?
Eur J Heart Fail. 2025 Apr;27(4):623-627. doi: 10.1002/ejhf.3614. Epub 2025 Feb 13.

本文引用的文献

1
Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.遗传性与野生型转甲状腺素蛋白淀粉样心肌病老年患者的患病率、特征及预后
Eur J Heart Fail. 2023 Apr;25(4):515-524. doi: 10.1002/ejhf.2776. Epub 2023 Jan 30.
2
Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome.双侧腕管综合征手术后 5 至 15 年后的心脏淀粉样变性筛查。
J Am Coll Cardiol. 2022 Sep 6;80(10):967-977. doi: 10.1016/j.jacc.2022.06.026.
3
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
用于治疗遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病患者的 vutrisiran 的疗效和安全性:一项随机临床试验。
Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23.
4
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.转甲状腺素蛋白淀粉样变性的患病率及临床结局:一项系统评价和荟萃分析。
Eur J Heart Fail. 2022 Sep;24(9):1677-1696. doi: 10.1002/ejhf.2589. Epub 2022 Aug 2.
5
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.遗传性转甲状腺素蛋白淀粉样变性病诊断与管理的新方法。
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):668-678. doi: 10.1136/jnnp-2021-327909. Epub 2022 Mar 7.
6
ATTR Amyloidosis: Current and Emerging Management Strategies: State-of-the-Art Review.转甲状腺素蛋白淀粉样变性:当前及新出现的管理策略:最新综述
JACC CardioOncol. 2021 Oct 19;3(4):488-505. doi: 10.1016/j.jaccao.2021.06.006. eCollection 2021 Oct.
7
A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction.一种循环的、疾病特异性的、与机制相关的生物标志物,用于诊断 ATTR 多发性神经病和预测对治疗的反应。
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9). doi: 10.1073/pnas.2016072118.
8
Quantification of Amyloid-β in Plasma by Simple and Highly Sensitive Immunoaffinity Enrichment and LC-MS/MS Assay.通过简单且高灵敏度的免疫亲和富集和 LC-MS/MS 分析定量测定血浆中的淀粉样蛋白-β。
J Appl Lab Med. 2021 Jul 7;6(4):834-845. doi: 10.1093/jalm/jfaa225.
9
Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic.心力衰竭门诊中野生型转甲状腺素蛋白心脏淀粉样变性的患病率。
ESC Heart Fail. 2021 Feb;8(1):745-749. doi: 10.1002/ehf2.13110. Epub 2020 Nov 17.
10
A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model.一种靶向聚集型转甲状腺素蛋白的新型单克隆抗体在实验模型中促进其清除及功能恢复。
Eur Heart J. 2020 Mar 21;41(12):1260-1270. doi: 10.1093/eurheartj/ehz695.